A 2024 retrospective cohort study by Lu et al., using the TriNetX database, evaluated outcomes in BC patients with obesity treated with GLP-1 RAs compared to other weight loss medications. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.